Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) closed the day trading at $17.36 up 4.01% from the previous closing price of $16.69. In other words, the price has increased by $+0.67 from its previous closing price. On the day, 832160 shares were traded. DCPH stock price reached its highest trading level at $17.73 during the session, while it also had its lowest trading level at $16.74.
Ratios:
For a better understanding of DCPH, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.59 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On October 30, 2023, Piper Sandler Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $23.
Stifel Upgraded its Hold to Buy on August 10, 2023, whereas the target price for the stock was revised from $14 to $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 16 when Kelly Thomas Patrick sold 3,010 shares for $15.62 per share. The transaction valued at 47,009 led to the insider holds 80,350 shares of the business.
Sherman Matthew L sold 2,615 shares of DCPH for $40,840 on Feb 16. The EVP & Chief Medical Officer now owns 108,739 shares after completing the transaction at $15.62 per share. On Feb 16, another insider, Martin Daniel C., who serves as the Chief Commercial Officer of the company, sold 2,267 shares for $15.62 each. As a result, the insider received 35,405 and left with 55,118 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DCPH now has a Market Capitalization of 1.40B and an Enterprise Value of 1.12B. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.59 while its Price-to-Book (P/B) ratio in mrq is 3.98. Its current Enterprise Value per Revenue stands at 6.87 whereas that against EBITDA is -5.37.
Stock Price History:
Over the past 52 weeks, DCPH has reached a high of $17.69, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is 15.30, while the 200-Day Moving Average is calculated to be 13.82.
Shares Statistics:
Over the past 3-months, DCPH traded about 572.33K shares per day on average, while over the past 10 days, DCPH traded about 522.39k shares per day. A total of 80.50M shares are outstanding, with a floating share count of 49.15M. Insiders hold about 39.18% of the company’s shares, while institutions hold 63.78% stake in the company. Shares short for DCPH as of Feb 15, 2024 were 5.51M with a Short Ratio of 9.63, compared to 4.97M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.82% and a Short% of Float of 9.09%.
Earnings Estimates
Current recommendations for the stock of the company come from 10 analysts. On average, analysts expect EPS of -$0.55 for the current quarter, with a high estimate of -$0.5 and a low estimate of -$0.63, while EPS last year was -$0.6. The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.49 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$1.96 and -$2.59 for the fiscal current year, implying an average EPS of -$2.2. EPS for the following year is -$1.67, with 10 analysts recommending between -$0.53 and -$2.39.
Revenue Estimates
9 analysts predict $46.08M in revenue for the current quarter. It ranges from a high estimate of $48.9M to a low estimate of $42M. As of the current estimate, Deciphera Pharmaceuticals Inc’s year-ago sales were $33.45M, an estimated increase of 37.80% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $48.8M, an increase of 27.40% less than the figure of $37.80% in the same quarter last year. There is a high estimate of $51.1M for the next quarter, whereas the lowest estimate is $44.1M.
A total of 9 analysts have provided revenue estimates for DCPH’s current fiscal year. The highest revenue estimate was $207.4M, while the lowest revenue estimate was $186.7M, resulting in an average revenue estimate of $199.84M. In the same quarter a year ago, actual revenue was $163.36M, up 22.30% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $258.88M in the next fiscal year. The high estimate is $397M and the low estimate is $215.9M. The average revenue growth estimate for next year is up 29.50% from the average revenue estimate for this year.
